PDP Pediapharm

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE
UNITED STATES 


Pediapharm Inc. (the "Corporation") (TSX VENTURE:PDP) is pleased to announce
that it has completed the previously-announced "bought deal" private placement
of 5,555,556 common shares of the Corporation (the "Common Shares") at a price
of $0.36 per Common Shares for gross proceeds of $2,000,000.16. 


The private placement was lead by Laurentian Bank Securities Inc. The Common
Shares are subject to a hold period expiring on June 22, 2014. 


The net proceeds of the private placement will be used to expand product
portfolio and for general working capital purposes. 


As a result of the private placement, there are 71,998,856 common shares of the
Corporation issued and outstanding. 


This news release is intended for distribution in Canada only and is not
intended for distribution to the United States newswire services or
dissemination in the United States. The securities being offered have not, nor
will they be registered under the United States Securities Act of 1933, as
amended, and may not be offered or sold within the United States or to, or for
the account or benefit of, U.S. persons absent U.S. registration or an
applicable exemption from the U.S. registration requirements. This release does
not constitute an offer for sale of securities in the United States. 


About Pediapharm Inc. 

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to
serving the needs of the pediatric community. Its mission is to bring to the
Canadian market the latest innovative pediatric products with the objective to
improve the health and the well-being of children in Canada. Since its debut in
2008, Pediapharm has entered into numerous commercial agreements with partners
from Canada and other countries around the world. The company's innovative
product portfolio includes NYDA(R); a breakthrough treatment for head lice;
EpiCeram(R) a non-steroid emulsion for eczema; KoolEffect(TM) which reduces the
symptoms of fever; and VapoLyptus(TM); a soothing vapour patch of Eucalyptus and
Camphor. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release. 


FORWARD LOOKING STATEMENTS 

This news release contains forward-looking statements and other statements that
are not historical. Such forward-looking statements are subject to known and
unknown risks, uncertainties and assumptions that could cause actual results to
vary materially from target results and the results or events predicted in these
forward-looking statements. As a result, investors are cautioned not to place
undue reliance on these forward-looking statements. 


The forward-looking statements contained in this news release are made as of the
date of this release. Except as required by applicable law, the Corporation
disclaims any intention and assumes no obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise. Forward-looking information reflects the current
expectations or belief of the Corporation based on information currently
available and such information is subject to a number of assumptions, risks and
uncertainties described in details at pp. 35 to 41 of the Management Information
Circular of Chelsea Acquisition Corporation dated November 12, 2013 available on
SEDAR at www.sedar.com and other risks associated with being a specialty
pharmaceutical company.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Sylvain Chretien, President and Chief Executive Officer
Pediapharm Inc.
514-762-2626 ext., 201
sylvain.chretien@pedia-pharm.com


Roland Boivin, Chief Financial Officer
Pediapharm Inc.
514-762-2626 ext., 202
roland.boivin@pedia-pharm.com

Pediapharm Inc. (TSXV:PDP)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024

Pediapharm Inc. (TSXV:PDP)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024